Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Full description

Bibliographic Details
Main Authors:	Thomas Blom, Roosmarijn Lurvink, Leonie Aleven, Maarten Mensink, Tom Wolfs, Miranda Dierselhuis, Natasha van Eijkelenburg, Kathelijne Kraal, Max van Noesel, Martine van Grotel, Godelieve Tytgat
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Oncology
Subjects:	neuroblastoma immunotherapy dinutuximab ch14.18 anti-GD2 antibody safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.601076/full

Similar Items

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Fiedler, S., et al.
Published: (2022)

T-cell mediated suppression of neuroblastoma following fractalkine gene therapy is amplified by targeted IL-2
by: Zeng, Yan
Published: (2006)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO
by: Nikolai Siebert, et al.
Published: (2020-01-01)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

Monitoring Immune Responses in Neuroblastoma Patients during Therapy
by: Celina L. Szanto, et al.
Published: (2020-02-01)

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
by: Nikolai Siebert, et al.
Published: (2017-10-01)

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
by: Nikolai Siebert, et al.
Published: (2018-10-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice
by: Sidra Maqbool, et al.
Published: (2019-02-01)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
by: Celina L. Szanto, et al.
Published: (2021-04-01)

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside
by: S. Faraj, et al.
Published: (2018-01-01)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
by: Sascha Troschke-Meurer, et al.
Published: (2019-12-01)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
by: Renske J. E. van den Bijgaart, et al.
Published: (2020-01-01)

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
by: Liyu Zhang, et al.
Published: (2021-12-01)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

4SCAR‐GD2‐modified T‐cell therapy in neuroblastoma with MYCN amplification: A case report with over 4‐year follow‐up data
by: Xiao Xu, et al.
Published: (2020-03-01)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
by: Jaume Mora, et al.
Published: (2021-03-01)

A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
by: Zhang L, et al.
Published: (2021-05-01)

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
by: Maxim Sorokin, et al.
Published: (2020-05-01)

Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma
by: Elwira Szychot, et al.
Published: (2016-09-01)

Monoclonal Antibody Therapies for High Risk Neuroblastoma
by: Furman WL
Published: (2021-06-01)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
by: Robyn T. Sussman, et al.
Published: (2020-03-01)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
by: Arthur Wingerter, et al.
Published: (2021-01-01)

Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment
by: Antonella Brizzolara, et al.
Published: (2020-11-01)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
by: Jaume Mora, et al.
Published: (2020-10-01)

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
by: Irina V. Kholodenko, et al.
Published: (2019-10-01)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
by: Bassel Nazha, et al.
Published: (2020-07-01)

The t(14;18) translocation is absent from endothelial and follicular dendritic cells of follicular lymphoma (FL) and shows heterogeneous presence in preserved FL mantle zones
by: Perikles Kosmidis, et al.
Published: (2018-05-01)

Presence of t(14;18) translocation in healthy individuals varies according to ethnic background in the Brazilian population
by: D. Levy, et al.

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
by: M. Fevzi Ozkaynak, et al.
Published: (2018-06-01)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
by: M. Fevzi Ozkaynak, et al.
Published: (2018-07-01)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
by: Christian Martin Seitz, et al.
Published: (2021-07-01)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
by: Thomas Blom, et al.
Published: (2021-08-01)

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
by: Julie Voeller, et al.
Published: (2019-12-01)